Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications

References

• AstraZeneca. Seroquel® (quetiapine fumarate) tablets/US prescribing information. Available at: http://www1.astrazeneca-us.com/pi/seroquel.pdf [Last accessed 9 July 2012]
   Google Scholar
• AstraZeneca UK Limited. Seroquel Summary of Product Characteristics (UK). Available at: http://www.medicines.org.uk/emc/medicine/2295 [Last accessed 16 November 2012]
   Google Scholar
• DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40:509-22
   PubMed Web of Science ®Google Scholar
• Winter HR, Earley WR, Hamer-Maansson JE, et al. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008;18:81-98
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63(Suppl 13):5-11
   PubMed Web of Science ®Google Scholar
• Reilly-Harrington N, Sachs GS. Psychosocial strategies to improve concordance and adherence in bipolar disorder. J Clin Psychiatry 2006;67:e04
   PubMedGoogle Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
   PubMed Web of Science ®Google Scholar
• Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006;67:1542-50
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-52
   PubMed Web of Science ®Google Scholar
• Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv 2011;62:1032-40
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8:232-41
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8
   PubMed Web of Science ®Google Scholar
• Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-15
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl 16):10-13
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51
   PubMed Web of Science ®Google Scholar
• Buckley PF, Wirshing DA, Bhushan P, et al. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 2007;21:129-41
   PubMed Web of Science ®Google Scholar
• Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets – US prescribing information. Available at: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf [Last accessed 25 October 2012]
   Google Scholar
• AstraZeneca. Seroquel XR – Summary of Product Characteristics for Ireland. Available at: http://www.medicines.ie/medicine/13032/SPC/Seroquel + XR + 50mg%2c + 150mg%2c + 200mg%2c + 300mg%2c + 400mg + prolonged-release + tablets/[Last accessed 18 May 2012]
   Google Scholar
• Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-20
   PubMed Web of Science ®Google Scholar
• Khan A, Joyce M, Atkinson S, et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011;31:418-28
   PubMed Web of Science ®Google Scholar
• Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010;25:103-15
   PubMed Web of Science ®Google Scholar
• Ganesan S, Agambaram V, Randeree F, et al. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008;24:21-32
   PubMed Web of Science ®Google Scholar
• Möller H-J, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol 2008;23:95-105
   PubMed Web of Science ®Google Scholar
• Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:199-204
   PubMed Web of Science ®Google Scholar
• Juckel G, Winter HR, Ståhle L, et al. The pharmacokinetics of extended release quetiapine fumarate are not affected by a light meal. Schizophr Res 2008;98:163-4
   PubMed Web of Science ®Google Scholar
• Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009;31:492-502
   PubMed Web of Science ®Google Scholar
• Riesenberg RA, Baldytcheva I, Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, Phase IV study. Clin Ther 2012;34:2202-11
   PubMed Web of Science ®Google Scholar
• Nord M, Nyberg S, Brogren J, et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 2011;14:1357-66
   PubMed Web of Science ®Google Scholar
• Nyberg S. PET-measured occupancy of the D2 receptor: a comparison of quetiapine fumarate immediate- and extended-release formulations in healthy subjects. Eur Psychiatry 2010;25:300, abs P01-70
   PubMedGoogle Scholar
• Sunkara G, Chilikuri DM. IVIVC: an important tool in the development of drug delivery systems. Drug Dev Deliv 2003;3(4)
   Google Scholar
• Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:832-42
   PubMed Web of Science ®Google Scholar
• Emborg C, Hallerback T, Jorgensen L, et al. A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark. Hum Psychopharmacol 2012;27:492-8
   PubMed Web of Science ®Google Scholar
• Dell’Osso B, Arici C, Dobrea C, et al. Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. Int Clin Psychopharmacol 2012;27:310-13
   PubMed Web of Science ®Google Scholar
• Eriksson L, Hallerbäck T, Jörgensen L, et al. Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized schizophrenic patients – a retrospective study. Ther Adv Psychopharmacol 2012;2:6217-26
   Google Scholar
• Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 2008;33:2303-12
   PubMed Web of Science ®Google Scholar
• Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur Psychiatry 2010;25(Suppl 1):1446, abstract PW01-27
   Google Scholar
• Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry 1992;33:115-20
   PubMed Web of Science ®Google Scholar
• Cana F. Mechanisms of action of atypical antipsychotics. CNS Spectr 2005;10:5-11
   Web of Science ®Google Scholar
• Bressan RA, Costa DC, Jones HM, et al. Typical antipsychotic drugs – D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002;56:31-6
   PubMed Web of Science ®Google Scholar
• Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:275-82
   PubMed Web of Science ®Google Scholar
• Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’? Clin Neurosci Res 2003;3:108-17
   Web of Science ®Google Scholar
• Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-39
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71:163-74
   PubMed Web of Science ®Google Scholar
• Thase M, Macfadden W, McCoy R, et al. Efficacy of quetiapine monotherapy in bipolar depression: a confirmatory double-blind, placebo-controlled study (The BOLDER II Study). Int J Neuropsychopharmacol 2006;9(Suppl 1):S237, abstract P03.035
   Google Scholar
• Stahl S. Psychopharmacology of Antidepressants. London, UK: Martin Dunitz Ltd, 2008
   Google Scholar
• Goldstein JM, Christoph G, Grimm S, et al. Quetiapine’s antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol 2007;17(Suppl 4):S401
   Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-9
   PubMed Web of Science ®Google Scholar
• Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69:81-6
   PubMed Web of Science ®Google Scholar
• Farde L, Mack RJ, Nyberg S, et al. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int Clin Psychopharmacol 1997;12(Suppl 1):S3-7
   PubMedGoogle Scholar
• Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-8
   PubMed Web of Science ®Google Scholar
• Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869-75
   PubMed Web of Science ®Google Scholar